A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)

Anders Johnsson, J.E. Frodin, A. Berglund, H. Hagman, J. Sundberg, D. Bergstrøm, René dePont Christensen, Nina Keldsen, Karen-Lise Garm Spindler, Anders Jakobsen

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearch

Original languageEnglish
Publication date2011
Publication statusPublished - 2011
EventASCO Annual Meeting 2011 - Chicago, United States
Duration: 3. Jun 20117. Jun 2011

Conference

ConferenceASCO Annual Meeting 2011
CountryUnited States
CityChicago
Period03/06/201107/06/2011

Cite this

Johnsson, A., Frodin, J. E., Berglund, A., Hagman, H., Sundberg, J., Bergstrøm, D., ... Jakobsen, A. (2011). A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). Abstract from ASCO Annual Meeting 2011, Chicago, United States.
Johnsson, Anders ; Frodin, J.E. ; Berglund, A. ; Hagman, H. ; Sundberg, J. ; Bergstrøm, D. ; Christensen, René dePont ; Keldsen, Nina ; Spindler, Karen-Lise Garm ; Jakobsen, Anders. / A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). Abstract from ASCO Annual Meeting 2011, Chicago, United States.
@conference{1660398ef893434e8ff95ee72abb9668,
title = "A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)",
author = "Anders Johnsson and J.E. Frodin and A. Berglund and H. Hagman and J. Sundberg and D. Bergstr{\o}m and Christensen, {Ren{\'e} dePont} and Nina Keldsen and Spindler, {Karen-Lise Garm} and Anders Jakobsen",
year = "2011",
language = "English",
note = "null ; Conference date: 03-06-2011 Through 07-06-2011",

}

Johnsson, A, Frodin, JE, Berglund, A, Hagman, H, Sundberg, J, Bergstrøm, D, Christensen, RD, Keldsen, N, Spindler, K-LG & Jakobsen, A 2011, 'A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)', ASCO Annual Meeting 2011, Chicago, United States, 03/06/2011 - 07/06/2011.

A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). / Johnsson, Anders; Frodin, J.E.; Berglund, A.; Hagman, H.; Sundberg, J.; Bergstrøm, D.; Christensen, René dePont; Keldsen, Nina; Spindler, Karen-Lise Garm; Jakobsen, Anders.

2011. Abstract from ASCO Annual Meeting 2011, Chicago, United States.

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearch

TY - ABST

T1 - A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)

AU - Johnsson, Anders

AU - Frodin, J.E.

AU - Berglund, A.

AU - Hagman, H.

AU - Sundberg, J.

AU - Bergstrøm, D.

AU - Christensen, René dePont

AU - Keldsen, Nina

AU - Spindler, Karen-Lise Garm

AU - Jakobsen, Anders

PY - 2011

Y1 - 2011

M3 - Conference abstract for conference

ER -

Johnsson A, Frodin JE, Berglund A, Hagman H, Sundberg J, Bergstrøm D et al. A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). 2011. Abstract from ASCO Annual Meeting 2011, Chicago, United States.